Dr. Christopher McCurdy - Kratom (Mitragyna Speciosa) as a potential therapy скачать в хорошем качестве

Dr. Christopher McCurdy - Kratom (Mitragyna Speciosa) as a potential therapy

A better quality version of this video can be found here:    • Dr. Christopher McCurdy - Kratom (Mitragyn...   Dr. Christopher McCurdy's presentation: "Kratom (Mitragyna speciosa) as a potential therapy for opioid dependance" at the Ethnopharmacologic Search for Psychoactive Drugs II: Tyringham Hall, Buckinghamshire, England (http://espd50.com) Christopher McCurdy, Ph.D., is a broadly trained medicinal chemist, behavioral pharmacologist and pharmacist whose research focuses on the design, synthesis and development of drugs to treat pain and drug abuse. For over 20 years, much of his research has focused on opioid, Neuropeptide FF and sigma receptor ligand/probe design, synthesis, pharmacological evaluation and development. He has been successful in discovering unique and selective tools for sigma receptors, NPFF receptors and opioid receptors. He is an internationally recognized expert on Kratom (Mitragyna speciosa), that is under investigation for opioid withdrawal syndrome. A significant portion of his career has been dedicated to the development of novel sigma receptor ligands, in collaboration with a variety of interdisciplinary groups, to generate and optimize selective ligands which could serve as critical experimental tools, and more recently, as potential medication development leads to attenuate the effects of cocaine, methamphetamine and pain. Most notably, he has developed a PET/MR imaging diagnostic agent for visualizing the origins of chronic, neuropathic pain by interacting with sigma receptors at the site of nerve damage. First-in-human studies are currently underway in a Phase 0 trial. In addition to his discovery chemistry roles, McCurdy serves as the director of the UF Translational Drug Development Core. Dr. McCurdy is currently President-Elect of the American Association of Pharmaceutical Scientists (AAPS) and also serves as the Co-Chair of the Special Interest Group on Drug Design and Discovery (DDD) of the International Pharmaceutical Federation (FIP).